Rifaximin for preventing acute graft-versus-host disease: Impact on plasma markers of inflammation and T-cell activation

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 4, 2013, Pages

  Qayed, Muna ^a,f   Langston, Amelia ^a   Chiang, Kuang Yueh ^a   August, Keith ^c   Hilinski, Joseph A ^a   Cole, Conrad R ^d   Rogatko, Andre ^e   Bostick, Roberd M ^a,b   Horan, John T ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f not available   (United States)

Author keywords

Acute graft versus host disease; Biomarkers; Rifaximin

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; INTERLEUKIN 6; MELPHALAN; QUINOLONE DERIVATIVE; RIFAXIMIN; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR; RIFAMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; BACTERIAL TRANSLOCATION; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOPROPHYLAXIS; INFLAMMATION; LEUKEMIA; MALE; MYCOSIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE ACTIVATION; VOMITING; ACUTE DISEASE; BLOOD; BONE MARROW TRANSPLANTATION; CASE CONTROL STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG EFFECT; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE; TRANSPLANTATION;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; CASE-CONTROL STUDIES; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INFLAMMATION; INTERLEUKIN-6; LEUKEMIA; LYMPHOCYTE ACTIVATION; MALE; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RIFAMYCINS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

MLCS; MLOWN;

EID: 84878624865     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31827e56af     Document Type: Article

References (19)

1. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754-2759.
2. Ferrara JL, Antin JH. The pathophysiology of graft-versushost-disease. In: Applebaum FR, Forman SJ, Negrin RS, et al, eds. Thomas' Hematopoietic Cell Transplantation. 4th ed. Oxford: Blackwell Publishing; 2009:208-221.
3. Jones JM, Wilson R, Bealmear PM. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res. 1971;45:577-588.
4. van Bekkum DW, Roodenburg J, Heidt PJ, et al. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst. 1974;52:401-404.
5. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versusleukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581-1589.
6. Beelen DW, Elmaagacli A, Muller KD, et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and longterm follow-up of an open-label prospective randomized trial. Blood. 1999;93:3267-3275.
7. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-812.
8. Fiorucci S, Distrutti E, Mencarelli A, et al. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66:246-256.
9. Hoover WW, Gerlach EH, Hoban DJ, et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis. 1993;16:111-118.
10. Goto H, Nakamura S. Liberation of endotoxin from Escherichia coli by addition of antibiotics. Jpn J Exp Med. 1980;50: 35-43.
11. Shenep JL, Barton RP, Mogan KA. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J Infect Dis. 1985;151:1012-1018.
12. Dofferhoff AS, Esselink MT, de Vries-Hospers HG, et al. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother. 1993;31:373-384.
13. Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood. 2009;114:891-900.
14. Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant. 1996;17: 185-190.
15. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113:273-278.
16. August KJ, Chiang KY, Bostick RM, et al. Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transplant. 2011;46:601-604.
17. Sepkowitz KA. Antibiotic prophylaxis in patients receiving hematopoietic stem cell transplant. Bone Marrow Transplant. 2002;29:367-371.
18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
19. Kowalchuk RK, Keselman HJ, Algina J, et al. The analysis of repeated measurements with mixed-model adjusted F tests. Educ Psychol Meas. 2004;64:224-242.